RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT

admin_news admin_news
Jul 14, 2025 - 09:30
0 0
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT
Read More